Randomized discontinuation trial of sorafenib (BAY 43-9006)

Cancer Biology and Therapy

Volumn 5, Issue 10, 2006, Pages 1270-1272

  Jain, Lokesh ^a,b   Venitz, Jürgen ^a   Figg, William D ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytostatic; Kinase inhibitor; Phase II; Renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; PLACEBO; SORAFENIB;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CLINICAL TRIAL; CYTOLOGY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIFE EXPECTANCY; MEDICAL ETHICS; SHORT SURVEY; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 33751116295     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.10.3290     Document Type: Short Survey

References (8)

1. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. Ann Intern Med 2000; 133:464-70.
2. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: Application to cytostatic antineoplastic agents. J Clin Oncol 2002; 20:4478-84.
3. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10:6388S-92S.
4. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006; 57:685-92.
5. Amery W, Dony J. A clinical trial design avoiding undue placebo treatment. J Clin Pharmacol 1975; 15:674-9.
6. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-12.
7. Orentlicher D. Placebo-controlled trials of new drugs: Ethical considerations. Diabetes Care 2001; 24:771-2.
8. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 2001; 19:265-72.